Treatment of Chronic Immune Thrombocytopenic Purpura (ITP)

First-Line Treatment Options

• The American Society of Hematology recommends prednisone (1 mg/kg orally for 21 days followed by tapering) as the primary first-line therapy for chronic ITP 1
• Initial response to corticosteroids occurs in 70-80% of patients, but sustained responses are seen in only 20-40% of cases 2
• Treatment decisions should be based on bleeding severity, bleeding risk, patient activity level, potential side effects, and patient preferences rather than platelet count alone 1
• Intravenous immunoglobulin (IVIg) at 0.4 g/kg/day for 5 days or 1 g/kg/day for 1-2 days can be used when rapid platelet increase is needed or when corticosteroids are contraindicated 3
• IV anti-D (50-75 μg/kg) can be used for Rh(D) positive, non-splenectomized patients as an alternative first-line option 3

Second-Line Treatment Options

• Thrombopoietin receptor agonists (TPO-RAs) are associated with high response rates and can be considered before splenectomy in patients who fail corticosteroid therapy 2
• Rituximab (anti-CD20 monoclonal antibody) achieves responses in 60% of patients with complete responses in 40% of patients 4
• Response to rituximab typically occurs within 1-8 weeks of treatment initiation 4
• Long-term responses with rituximab are documented in 20-30% of cases 2
• Splenectomy has historically been the gold standard second-line therapy with initial response rates of 80% and long-term responses in approximately 60-65% of patients 4, 2

Third-Line Treatment Options

• Azathioprine (1-2 mg/kg daily) achieves responses in up to two-thirds of patients but may take 3-6 months for effect 4
• Cyclosporin A (5 mg/kg/day initially, then 2.5-3 mg/kg/day) shows response rates of 50-80% with onset within 3-4 weeks 4
• Cyclophosphamide (1-2 mg/kg orally daily or 0.3-1 g/m² IV every 2-4 weeks) produces responses in 24-85% of patients 4
• Danazol (200 mg 2-4 times daily) achieves responses in up to 67% of patients but requires 3-6 months of treatment 4
• Dapsone (75-100 mg daily) shows responses in up to 50% of patients within 3 weeks 4
• Mycophenolate mofetil (1000 mg twice daily) achieves responses in up to 75% of patients within 4-6 weeks 4

Special Considerations

• Prolonged corticosteroid use should be avoided due to significant side effects including weight gain, mood alterations, hypertension, diabetes, osteoporosis, and increased infection risk 2
• Treatment for chronic ITP should be tailored to maintain a hemostatic platelet count (typically >30-50 × 10^9/L) rather than normalizing platelet counts 1
• The decision to treat should be based primarily on bleeding symptoms rather than platelet count alone, though counts <20-30 × 10^9/L generally warrant treatment 1
• In children with chronic ITP, the goal is to maintain hemostatic platelet counts while minimizing the use of prolonged corticosteroid therapy 5
• Cytotoxic drugs should be used with extreme caution in children with chronic ITP 5

Long-Term Treatment Options for Chronic Immune Thrombocytopenic Purpura (ITP)

First-Line and Second-Line Treatment Options

• The American Society of Hematology recommends thrombopoietin receptor agonists (TPO-RAs) as the mainstay of long-term treatment for chronic ITP due to their high response rates, sustained efficacy, and favorable safety profile compared to other options 6, 7
• TPO-RAs (romiplostim, eltrombopag) are the preferred second-line therapy for long-term management of chronic ITP, with overall platelet response rates of 88% in non-splenectomized and 79% in splenectomized patients 6, 7, 8
• Sustained responses for up to 4 years with continuous administration of TPO-RAs have been documented, with potential for remission in up to 30% of patients after tapering and discontinuation 6, 7, 8

Treatment Considerations and Monitoring

• The American College of Physicians suggests that treatment should aim to maintain a hemostatic platelet count (>30-50 × 10^9/L) rather than normalizing platelet counts, and decision to treat should be based primarily on bleeding symptoms rather than platelet count alone 7
• For patients on TPO-RAs who achieve stable platelet counts at the lowest dose, consider holding therapy to monitor for potential remission, and patients who do not respond to one TPO-RA may respond to the alternate TPO-RA 7
• Abrupt interruptions of TPO-RAs or excessive dose adjustments may cause platelet fluctuations and should be avoided, especially in patients with a history of splenectomy or romiplostim use 7

Treatment Algorithm and Common Pitfalls

• Prolonged corticosteroid use (>6-8 weeks) should be avoided due to significant side effects, and patients requiring on-demand administration of corticosteroids after completing first-line treatment should be considered non-responders and promptly switched to second-line therapy 6
• TPO-RAs were previously thought to require lifelong administration, but evidence now shows up to 30% of patients may achieve remission after discontinuation, and when switching between TPO-RAs due to lack of efficacy, most patients will respond to the alternate agent 6, 7

Initial Treatment of Adult ITP

First-Line Corticosteroid Options

• The American Society of Hematology (ASH) guidelines found increased platelet count response at 7 days with dexamethasone (RR 1.31; 95% CI 1.11-1.54) and higher remission rates (RR 2.96; 95% CI 1.03-8.45) 9
• High-dose dexamethasone 40 mg/day for 4 days offers up to 90% initial response rates and 50-80% sustained response rates, with higher initial and sustained response rates compared to conventional prednisone therapy 9

Emergency Treatment Protocol

• For patients with uncontrolled bleeding or requiring emergency surgery, combining prednisone and IVIg together is recommended, with high-dose methylprednisolone also being useful in emergency settings 10
• Other rapidly acting therapies include platelet transfusion (possibly in combination with IVIg) and emergency splenectomy 10

Common Pitfall to Avoid

• The American Society of Hematology (ASH) guidelines suggest corticosteroids alone rather than rituximab plus corticosteroids for initial therapy, as the addition increases treatment costs without sufficient evidence of benefit to justify routine use 9
• Rituximab plus corticosteroids shows higher durable response (RR 1.70; 95% CI 1.34-2.16), but there was no difference in preventing major bleeding or mortality, and no HRQoL data available 9

Methylprednisolone vs IVIG in ITP: Treatment Recommendation

Evidence-Based Treatment Selection

• The American Society of Hematology suggests that corticosteroids, including methylprednisolone, are the preferred first-line therapy over IVIG for adults with newly diagnosed ITP, due to equivalent efficacy, lower cost, and acceptable safety profile 11, 12
• Corticosteroids should be chosen over IVIG as initial therapy because response rates are equivalent, with both achieving 70-90% initial response rates, and no significant difference in durable response, remission, or prevention of major bleeding 13
• IVIG is significantly more expensive than corticosteroids without demonstrable superiority in clinical outcomes, making cost considerations substantial 12, 13
• Methylprednisolone achieves response in 4.7 days, compared to 8.4 days with standard prednisone, and 2-4 days with IVIG 11

Specific Methylprednisolone Regimens

• High-dose methylprednisolone (30 mg/kg/day for 7 days) produces response rates as high as 95% 11
• High-dose methylprednisolone (30 mg/kg/day for 7 days) results in a sustained response (>50 × 10⁹/L) at 39 months in 23% of patients 11

When IVIG Should Be Considered Instead

• IVIG should be reserved for emergency situations with uncontrolled bleeding, requiring the most rapid platelet increase, which responds within 24 hours 11
• IVIG should be considered for pre-operative preparation when surgery cannot be delayed 11
• IVIG should be used in cases of contraindications to corticosteroids, such as uncontrolled diabetes, active infection, or psychiatric instability 11

Pediatric Considerations

• The American Society of Hematology guidelines suggest corticosteroids rather than IVIG for children with newly diagnosed ITP and non-life-threatening mucosal bleeding, with a conditional recommendation 13

Critical Safety Considerations

• Prolonged courses of methylprednisolone (>6-8 weeks) should be avoided due to cumulative toxicity, including osteoporosis, avascular necrosis, and immunosuppression 12
• IVIG has a black box warning for thrombosis and renal failure, particularly in elderly, diabetic, or volume-depleted patients 13
• IVIG can cause severe headaches, which may be debilitating, and has an anaphylaxis risk in IgA-deficient patients 11, 13

Common Pitfalls to Avoid

• IVIG should not be used routinely as first-line therapy when corticosteroids are appropriate, as this wastes resources without improving outcomes 12, 13
• Corticosteroids should not be continued beyond 6-8 weeks, as prolonged use causes substantial morbidity without additional benefit 12

Methylprednisolone vs IVIG in ITP Treatment

Primary Treatment Recommendation

• For patients with uncontrolled bleeding or requiring emergency surgery, the American Society of Hematology suggests combining prednisone and IVIG together rather than choosing one over the other, as this approach achieves faster response rates 14
• IVIG at 1 g/kg as a one-time dose (or 0.4 g/kg/day for 5 days) may be used in conjunction with corticosteroids if more rapid platelet increase is required, with a moderate strength of evidence 15, 14

Emergency/Urgent Scenarios

• High-dose methylprednisolone is specifically useful in emergency settings with active CNS, GI, or genitourinary bleeding, with a high response rate 14
• In emergency bleeding or pre-operative scenarios, combining high-dose methylprednisolone with IVIG achieves the fastest response, according to the American Society of Hematology 14

Critical Safety Considerations

• IVIG has a black box warning for thrombosis and renal failure, particularly in elderly, diabetic, or volume-depleted patients, with a high strength of evidence 14